Efficacy and safety of compound Qingdai enema in rapidly alleviating inflammatory activity in ulcerative colitis: a prospective study
Frontiers in Pharmacology · 10.06.2026 · 17
DOI: 10.3389/fphar.2026.1776775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.06.2026. Verfasst von Yao Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim of the Study To observe the efficacy and safety of CQE in rapidly alleviating inflammatory activity in UC. Materials and Methods CQE extracts were analyzed by UHPLC–Q Exactive Orbitrap–HRMS. This study used a self-controlled design before and after treatment. A total of 114 UC patients were included and treated with traditional rectal enema administration of CQE. Among them, 107 patients completed the treatment, and 101 patients with complete clinical and laboratory data were included in the final analysis. The primary clinical intestinal symptoms, mucosal endoscopic and pathological changes, laboratory indicators, quality of life scores, and adverse reactions were compared before and after 14 days of enema treatment. A historical comparison was made with previous studies. The expression of intestinal tight junction proteins in the colons of UC patients during active periods was detected using Quantitative Real-time PCR (RT-qPCR) and Western blot (WB).
Results
The main compounds in CQE were identified, including Gallic acid, Matrine, Oxysophocarpine, Ellagic acid, Prim-O-glucosylcimifugin, Cytisinicline, Danshensu, Protocatechuic acid, Cimifugin, Salvianolic acid A Cytisinicline, Indigo, Indirubin, Tryptanthrin and others. The primary endpoint, defined as the change in modified Mayo score, showed a significant improvement after 14 days of CQE treatment ( P < 0.001). The clinical response rate was 94.06% (95/101), and the clinical remission rate was 66.34% (67/101). The endoscopic mucosal healing rate was 76.24% (77/101), and the histological remission rate was 38.61% (39/101). Compared to before treatment, post-treatment scores for clinical intestinal symptoms, Mayo endoscopic scores (MES), Geboes index, fecal calprotectin (FC), and fecal occult blood test (OB) were significantly reduced ( P < 0.001). The UCEIS score for the distal rectum and sigmoid colon showed more improvement than the proximal colon ( P < 0.01). Hemoglobin (HGB), albumin (ALB), and quality of life scores increased ( P < 0.05), while liver and kidney function indicators showed no abnormal elevations after treatment ( P < 0.05). Compared to historical data from previous studies using steroids and biologics, CQE significantly improved clinical and endoscopic remission rates. RT-qPCR and WB results demonstrated that the herbal enema helps repair the intestinal mucosal barrier in UC patients.
Conclusion
CQE can rapidly alleviate inflammatory activity in UC within 14 days and improve patients’ quality of life, with a low incidence of adverse events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China.
- Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
- Department of General Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China.
- Medical Department for Senior Cadres, The Third Affiliated Hospital of Zhejiang Chinese Medical University (Zhongshan Hospital of Zhejiang Province), Hangzhou, China.
- Department of Gastroenterology, Yuyao Traditional Chinese Medicine Hospital, Ningbo, China.
Zitieren
APA
Huang, Y., Qin, D., Yang, Q., Yang, X., Fang, Y., Zheng, S., Zhang, C., & Liu, S. (2026). Efficacy and safety of compound Qingdai enema in rapidly alleviating inflammatory activity in ulcerative colitis: a prospective study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1776775
Vancouver
Huang Y, Qin D, Yang Q, Yang X, Fang Y, Zheng S, et al. Efficacy and safety of compound Qingdai enema in rapidly alleviating inflammatory activity in ulcerative colitis: a prospective study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1776775
BibTeX
@article{Huang2026,
author = {Huang, Yao and Qin, DanPing and Yang, Qiang and Yang, Xinyan and Fang, YiWen and Zheng, SiHui and Zhang, ChunLi and Liu, Shan},
title = {Efficacy and safety of compound Qingdai enema in rapidly alleviating inflammatory activity in ulcerative colitis: a prospective study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1776775}
}
EUVIMED